All your MA & HTA needs in one place.

About us

Find out more about our history, values and Team.
Explore

Offer

See how we turn clinical data into market access strategies.
Explore

Publications

Read our latest publications.
Explore

Team

MAHTA is first and foremost about people who are dedicated to their work and constantly improving their knowledge, skills and competence.

Meet our team

Partnership

The reason for our immense pride, but also the measurable effect of our daily work, is increased access to effective forms of treatment and improve the quality of life of patients worldwide.

Explore

Bespoke solutions

We support the companies we work with at all stages of the reimbursement process. We offer knowledge, experience and a professional, flexible approach so that the solutions we propose are appropriate, effective and efficient.

Explore

in numbers

400

Over 400

successfully completed

reimbursement processes.

covering HTA.

40

Cooperation with over

40 renowned

specialists from various

areas of expertise.

50

Over 50 international processes successfully implemented.

News

Cost-utility analysis of linzagolix 200 mg plus add-back therapy (linzagolix + ABT) for the symptomatic treatment of endometriosis.

We are pleased to announce that MAHTA Intl. Team, in cooperation with Theramex and Decisive Consulting, will present the study “Cost-utility analysis of linzagolix 200 mg plus add-back therapy (linzagolix + ABT) for the symptomatic treatment of endometriosis” at ISPOR Europe 2025.
Explore

Indirect treatment comparison of biochemical control between pasireotide LAR and pegvisomant as second-line therapies for acromegaly, based on real-world evidence.

We are thrilled to announce that the MAHTA Intl. Team, in cooperation with Recordati Rare Diseases, and Professor Sabrina Chiloiro, has conducted a paradigm-shifting study.
Explore

Cost Comparison of Symptom Treatment in Atopic Dermatitis Using Upadacitinib and Dupilumab in Poland.

We are excited to share that the abstract entitled “Cost Comparison of Symptom Treatment in Atopic Dermatitis Using Upadacitinib and Dupilumab in Poland’’, developed by the MAHTA Team, will be presented at the ISPOR Europe 2025 conference in Glasgow.
Explore
Other news

Publications

Matching‑Adjusted Indirect Comparison of Osilodrostat Versus Metyrapone for the Treatment of Cushing’s Syndrome

Hickey C., Gueron B., Schmidt F., Tyas E., Binowski G., Pivonello R.
Open

Budget Impact Analysis of Risdiplam in the Treatment of Newborn Spinal Muscular Atrophy Patients in Poland

Strachota S., Malysiak-Szpond S., Binowski G., Książek P., Sutherland C.S., Pruszko C.
Open

Cost-Effectiveness of Glycopyrronium Bromide Oral Solution for the Management of Severe Sialorrhea in Children With Cerebral Palsy in Poland

Łabęcka D., Binowski G., Książek P., Rynkiewicz S., Pruszko C.
Open
Other publications